U.S. Software Stock News

NYSE:VZ
NYSE:VZTelecom

Verizon Consumer Shakeup Tests Valuation And Earnings Support Narrative

Verizon Communications (NYSE:VZ) has announced leadership changes in its Consumer Group. Sowmyanarayan Sampath is departing from his role as CEO of the Consumer Group. Alfonso Villanueva has been appointed interim CEO of Verizon's Consumer Group as part of a wider transformation effort. Verizon's Consumer Group is the core of the company’s wireless and broadband business, serving millions of retail customers across the US. Executive changes in this unit matter because they can influence how...
NasdaqGS:OTTR
NasdaqGS:OTTRElectric Utilities

Otter Tail (OTTR) Margins Hold Above 21% Challenging Bearish Earnings Narrative

Otter Tail (OTTR) has just posted its FY 2025 numbers, with fourth quarter revenue of US$308.1 million and basic EPS of US$1.24, alongside trailing twelve month revenue of about US$1.3 billion and EPS of US$6.59 setting the backdrop. Over recent periods, revenue has ranged from US$303.1 million in Q4 2024 to US$337.4 million in Q1 2025, while quarterly EPS has moved between US$1.31 and US$2.04, giving investors a clear read on how margins are holding up against this revenue base. With a...
NasdaqCM:RGC
NasdaqCM:RGCPharmaceuticals

Regencell Bioscience Holdings (RGC) Valuation After Insider Lock Up Extension And Rapid Share Price Momentum

Insider lock up extension puts Regencell Bioscience Holdings (RGC) insider activity in focus Regencell Bioscience Holdings (RGC) has extended insider lock up commitments for directors and employees by one year, covering previously granted stock options and keeping insiders restricted from selling for a longer period. See our latest analysis for Regencell Bioscience Holdings. The lock up extension comes after a sharp shift in sentiment, with a 90 day share price return of 150.16% and year to...
NYSE:FDS
NYSE:FDSCapital Markets

FactSet Expands AI Offerings As Shares Trade Well Below Targets

FactSet Research Systems (NYSE:FDS) has partnered with Kepler Cheuvreux to broaden aftermarket research coverage across EMEA, using AI to deliver more tailored research content to clients. The company has also launched a beta version of AI Doc Ingest for its Cobalt platform, aimed at automating document processing for private capital managers. These moves highlight FactSet's focus on expanding its global research footprint and refining data workflows for institutional investors and private...
NYSE:BAX
NYSE:BAXMedical Equipment

Baxter International (BAX) Is Down 5.5% After Wider Losses Offset Revenue Gain And Muted 2026 Outlook

Baxter International Inc. reported past fourth-quarter 2025 sales of US$2,974 million, up from US$2,753 million a year earlier, but the company’s net loss widened to US$1,128 million amid higher goodwill impairments and ongoing margin pressures. Alongside reaffirming a modest quarterly dividend and completing a long-running share repurchase program, Baxter guided to flat to 1% U.S. GAAP sales growth for 2026, underscoring a focus on balance sheet repair and operational reshaping following...
NasdaqCM:SEZL
NasdaqCM:SEZLDiversified Financial

A Look At Sezzle (SEZL) Valuation After Launching An Unlimited Mobile Plan

Sezzle (SEZL) is stepping beyond point of sale lending with the launch of Sezzle Mobile, an unlimited phone plan starting at $29.99 per month inside its app, using embedded connectivity on AT&T’s network. See our latest analysis for Sezzle. Despite the Sezzle Mobile launch and other recent partnerships such as the David's Bridal collaboration, Sezzle’s share price return has been mixed, with a 20.99% 90 day gain but a 7.45% 30 day decline and a 15.01% one year total shareholder return off a...
NYSE:DAC
NYSE:DACShipping

Assessing Danaos (DAC) Valuation After Strong 2025 Results And New Dividend

Why Danaos is in Focus After Its Latest Results Danaos (DAC) just released its fourth quarter and full year 2025 results alongside a new dividend declaration, giving investors fresh data on profitability and cash returns to shareholders. The company reported quarterly sales of US$266.27 million and net income of US$117.91 million, and declared a US$0.90 per share dividend payable in early March 2026. See our latest analysis for Danaos. Danaos shares trade at US$107.31 after a 1 day share...
NYSE:POST
NYSE:POSTFood

The Bull Case For Post Holdings (POST) Could Change Following Expanded Buybacks And Leadership Shake-Up

Post Holdings has recently reported first-quarter 2026 results, completed a US$122.1 million buyback tranche, authorized a new US$500 million repurchase program, amended its articles of incorporation, and announced several leadership changes, including a new CEO for Post Consumer Brands and two additions to its Board. These moves collectively highlight Post’s focus on capital returns and governance, while placing fresh leadership at the center of its largest consumer and pet food...
NYSE:BX
NYSE:BXCapital Markets

Is It Time To Reassess Blackstone (BX) After The Recent Share Price Slide?

If you are wondering whether Blackstone's current share price reflects its true worth, you are not alone. The stock has drawn attention from investors trying to work out if it still offers value after recent moves. The share price closed at US$131.39, with a 1.8% decline over the last 7 days, a 19.6% decline over the last 30 days, a 17.3% decline year to date and an 18.5% decline over the last year, while the 3 year and 5 year returns sit at 58.9% and 124.9% respectively. These mixed return...
NasdaqGM:IOVA
NasdaqGM:IOVABiotechs

Is Real‑World Amtagvi Response Data Altering The Investment Case For Iovance Biotherapeutics (IOVA)?

In early February 2026, Iovance Biotherapeutics reported real-world retrospective data showing a best-in-class clinical profile and unprecedented response rates for its commercial T cell therapy Amtagvi (lifileucel) in patients with advanced, unresectable or metastatic melanoma. This real-world evidence suggests Amtagvi could play a more central role in the treatment landscape for previously treated advanced melanoma, potentially reinforcing physician confidence in TIL-based therapies. We’ll...
NasdaqGS:MANH
NasdaqGS:MANHSoftware

Is Manhattan Associates (MANH) Quietly Recasting Its Cloud Moat With Record Bookings And New AI Agents?

In early 2026, Manhattan Associates reported a record fourth quarter for 2025, highlighted by all-time high cloud bookings and a broad increase in its 2026 guidance. The company also introduced commercial AI agents that management believes can immediately boost upsell potential across its cloud customer base through greater automation and productivity. We’ll now examine how Manhattan Associates’ record cloud performance and AI agent launch could shape the company’s broader investment...
NasdaqGS:OKTA
NasdaqGS:OKTAIT

Okta Targets Shadow AI And Threat Actors As Shares Trade Below Targets

Okta has introduced new shadow AI agent discovery capabilities within its Identity Security Posture Management product, targeting unsanctioned AI tool usage inside organizations. The company also released research on North Korean threat actors using false identities to secure remote employment and abuse corporate access. Both developments highlight emerging risks around AI adoption and identity abuse that could affect how enterprises think about security controls. For investors tracking...
NasdaqGS:ZION
NasdaqGS:ZIONBanks

A Look At Zions Bancorporation (ZION) Valuation After New US$500 Million Senior Notes Pricing

Zions Bancorporation National Association (ZION) recently priced US$500,000,000 of fixed to floating rate senior notes due 2029, a funding move intended to pay down short term borrowings and adjust its interest rate exposure. See our latest analysis for Zions Bancorporation National Association. At a latest share price of US$61.53, Zions has seen a 22.01% 90 day share price return alongside an 11.99% 1 year total shareholder return. This suggests momentum has been building as investors react...
NasdaqGM:EXPI
NasdaqGM:EXPIReal Estate

Is It Time To Revisit eXp World Holdings (EXPI) After Prolonged Share Price Weakness

If you are wondering whether eXp World Holdings at around US$7.50 is a bargain or a value trap, you are not alone, and this article is built to help you frame that question clearly. The share price is around US$7.50, with returns of 2.7% decline over 7 days, 21.4% decline over 30 days, 17.6% decline year to date, 32.3% decline over 1 year and 41.2% decline over 3 years. This raises fair questions about how the market currently views its prospects and risks. Recent news coverage has focused...
NasdaqCM:IGIC
NasdaqCM:IGICInsurance

How Expected Earnings Decline Amid Revenue Growth Will Impact International General Insurance Holdings (IGIC) Investors

International General Insurance Holdings Ltd. recently reported that analysts expected a year-over-year earnings decline alongside higher revenues for the quarter ended December 2025, ahead of its earnings release on February 24. This combination of weaker earnings and stronger top-line performance has sharpened attention on how management will frame business conditions and future profitability during the earnings call. We’ll now examine how anticipation of lower earnings despite higher...
NasdaqGS:BKNG
NasdaqGS:BKNGHospitality

Booking Holdings Links Route 66 Centennial Deal To Valuation Story

Booking.com, part of Booking Holdings (NasdaqGS:BKNG), has been named Official Travel Partner of the Route 66 Centennial. The partnership centers on the 2026 centennial celebrations of Route 66, a year-long series of road trip themed events across the historic highway. The agreement positions Booking.com as a key platform for travelers planning lodging and related services along the Route 66 corridor. For Booking Holdings, known for its global travel brands and online booking platforms,...
NasdaqGS:FFIV
NasdaqGS:FFIVCommunications

Is F5’s AI‑Focused Scality Integration Reshaping Its Hybrid Data Strategy and Investment Narrative (FFIV)?

On 18 February 2026, F5 and Scality announced an expanded partnership that integrates F5’s Application Delivery and Security Platform with Scality’s highly scalable, S3-compatible object storage to support secure, high-performance AI, analytics, and data-intensive workloads across on-premises, cloud-native, and hybrid environments. This joint architecture could matter for enterprises because it aims to remove data bottlenecks and complexity as AI adoption and compliance requirements...
NYSE:ROK
NYSE:ROKElectrical

Rockwell Automation (ROK) Is Down 5.8% After Raising FY26 Guidance And Filing ESOP Share Shelf - Has The Bull Case Changed?

Rockwell Automation recently reported stronger first-quarter fiscal 2026 results, raised its full-year earnings guidance, affirmed its US$1.38 quarterly dividend, and filed a US$4.18 billion shelf registration for 10,600,000 common shares tied to an ESOP-related offering. Together with ongoing share repurchases and growing adoption of its automation and digital twin solutions, these updates highlight Rockwell Automation’s focus on both shareholder returns and expanding its higher-value...
NasdaqGM:EYPT
NasdaqGM:EYPTPharmaceuticals

Is EyePoint’s New Commercial Chief the Missing Piece in the DURAVYU Story for EYPT Investors?

EyePoint, Inc. recently appointed Michael Campbell as Chief Commercial Officer, tasking him with leading commercial strategy and launch preparation for DURAVYU, the company’s Phase 3 wet age-related macular degeneration and diabetic macular edema candidate. Campbell’s long history of building ophthalmology franchises and launching eye-care products at companies such as Genentech, Novartis, Shire, and Opthea could materially shape how EyePoint brings DURAVYU to market. Now we’ll examine how...
NYSE:PRG
NYSE:PRGConsumer Finance

Weaker 2025 Results and Cautious 2026 Outlook Could Be A Game Changer For PROG (PRG)

PROG Holdings reported its fourth-quarter and full-year 2025 results, with sales, revenue, net income, and earnings per share all lower than the prior year, while also completing a multi‑year US$992.71 million share repurchase program covering 27,715,844 shares. Alongside these results, the company issued 2026 guidance that points to pressure on revenue and earnings from continuing operations, setting a cautious tone around its profit outlook despite prior expectations for steady digital and...
NYSE:AOS
NYSE:AOSBuilding

How A. O. Smith’s Q4 EPS Beat and Executive Stock Moves Will Impact A. O. Smith (AOS) Investors

A. O. Smith recently reported its fourth-quarter 2025 results, with earnings per share of US$0.90 coming in above analyst expectations while revenue fell short, and senior executive Darrell W. Schuh disclosed selling 356 shares and receiving 1,460 restricted stock units. This combination of stronger profitability and routine executive equity activity highlights how A. O. Smith is balancing near-term operational pressures with long-term incentive alignment for leadership. We will now examine...
NasdaqGS:GNTX
NasdaqGS:GNTXAuto Components

Is Gentex’s New Tactical VPU a Meaningful Step Toward Diversification for GNTX’s Investment Story?

Gentex Corporation recently launched the Ops-Core Voice Projection Unit (VPU), an add-on to its Special Operations Tactical Respirator that enhances mission-critical voice clarity with three adjustable volume levels and integration into existing communication systems for tactical operators. This move extends Gentex’s communication suite beyond its core automotive and dimmable glass products, highlighting how defense-oriented innovation can broaden its end-market exposure. Next, we’ll examine...
NasdaqGM:ADMA
NasdaqGM:ADMABiotechs

ADMA Biologics CEO Trading Plan Sparks Questions On Valuation Gap

ADMA Biologics CEO Adam Grossman executed a pre-arranged sale of company shares. The transaction also involved the exercise of previously granted stock options. The activity represents insider trading carried out under an established trading plan. For investors watching ADMA Biologics, ticker NasdaqGM:ADMA, this insider activity comes with the stock last closing at $15.95. The company’s long term track record includes very large returns over 3 and 5 years, while the 1 year return is close...
NYSE:MRK
NYSE:MRKPharmaceuticals

Merck Mayo AI Partnership Aims To Sharpen Drug Discovery Decisions

Merck (NYSE:MRK) and Mayo Clinic announced a new research and development partnership focused on using artificial intelligence and multimodal clinical data for drug discovery and development. The collaboration combines Mayo Clinic's large clinical and genomic datasets with Merck's AI driven virtual cell technologies to support earlier stage drug research. Mayo Clinic characterized this as its largest collaboration with a global biopharmaceutical company, highlighting the scale of the data...